RS Crum Inc. Takes $47,000 Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI)

RS Crum Inc. acquired a new stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) in the 4th quarter, Holdings Channel reports. The firm acquired 40,463 shares of the company’s stock, valued at approximately $47,000.

Several other hedge funds also recently modified their holdings of CLDI. Red Wave Investments LLC increased its stake in Calidi Biotherapeutics by 74.0% during the 4th quarter. Red Wave Investments LLC now owns 80,828 shares of the company’s stock valued at $93,000 after purchasing an additional 34,367 shares in the last quarter. Drive Wealth Management LLC bought a new stake in Calidi Biotherapeutics during the 4th quarter valued at $104,000. CPR Investments Inc. increased its stake in Calidi Biotherapeutics by 80.4% during the 4th quarter. CPR Investments Inc. now owns 101,000 shares of the company’s stock valued at $116,000 after purchasing an additional 45,000 shares in the last quarter. Finally, HighTower Advisors LLC bought a new stake in Calidi Biotherapeutics during the 4th quarter valued at $118,000. Institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Stock Performance

Shares of CLDI stock opened at $0.85 on Friday. The firm has a fifty day simple moving average of $1.00 and a two-hundred day simple moving average of $1.29. Calidi Biotherapeutics, Inc. has a 12 month low of $0.58 and a 12 month high of $8.30.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.